It is well documented that organic cation transporter 2 (OCT2) plays important roles in the cellular accumulation and consequent cytotoxicity of platinum complexes containing the (1R,2R)-cyclohexane-1,2-diamine (DACH) ligand.[21] OCT2-mediated cellular uptake has been suggested as a leading factor responsible for the sensitivity of colorectal cancer to oxaliplatin.[21] Because the Glc-Pts reported here bear the chelating DACH ligand, we investigated the potential of 1 to undergo translocation via OCT2, a transporter overexpressed in certain types of cancer cells and tumor samples from patients.[21–22] Expression of OCT2 in a panel of cancer cell lines was confirmed by Western blotting analysis (Figure S10b). A2780 cells were incubated with 10 μM 1 for 8 h in the presence or absence of EDG and/or the OCT2 inhibitor cimetidine (Ctd); oxaliplatin was employed as a positive control. In the presence of EDG, uptake of 1 was reduced by 50%, whereas the uptake levels of 4 and oxaliplatin were reduced by only 25% and 30%, respectively (Figure 2d). The OCT2 inhibitor Ctd reduces the uptake of the positive control compound oxaliplatin by 70%. Assays with Ctd revealed reductions of 45% and 35% in the cellular uptake of 1 and 4, respectively. These results support the involvement of OCT2 in the cellular internalization of both 1 and 4. The uptake of 1 was further decreased by 20% (p < 0.001) following treatment with a mixture of EDG and Ctd, compared to treatment with Ctd alone. These results further confirm the involvement of glucose transporters in the cellular uptake of 1 and indicate that OCT2 facilitates the cellular accumulation of 1 as well.